Ipamorelin
A growth hormone secretagogue studied in early human trials; not FDA-approved as a finished drug product, and its compounding eligibility has changed over time — a licensed pharmacy can confirm today's status.
What it is
Ipamorelin is a growth-hormone secretagogue — it prompts the pituitary to release growth hormone in pulses. It went through early-phase human trials decades ago for post-operative gut recovery, which were discontinued, and it was never approved as a drug.
Its regulatory story is unusually instructive: FDA placed ipamorelin in Category 2 of its interim compounding list in September 2023, then removed it in September 2024 after the nomination was withdrawn, and its eligibility has continued to be reviewed since. Translation: whether a licensed pharmacy can compound it is a moving target that only a licensed pharmacy can answer on a given day.
What researchers have actually studied it for
Growth-hormone release in early clinical research; discontinued trials in post-operative recovery. No approved indication.
How it works
Ipamorelin activates the ghrelin receptor (GHS-R) on the pituitary, triggering pulses of GH release. Its reputation for selectivity comes from early studies showing minimal spillover into cortisol, prolactin or appetite signaling at tested doses — the 'polite' member of the secretagogue family.
Where it came from
Developed by Novo Nordisk in the 1990s during the industry's GH-secretagogue push, ipamorelin reached phase 2 for post-operative ileus before the program was dropped. Two decades later it resurfaced as the compounding world's favorite GH peptide, usually paired with CJC-1295.
What the research record actually contains
- Early clinical pharmacology: clean GH-release curves with limited cortisol/prolactin effects.
- Discontinued phase 2 work in post-operative gut motility.
- No controlled trials on muscle, fat, recovery, sleep or aging outcomes in healthy adults — the uses it's marketed for.
What's known about risks
Short-term studies reported good tolerability, which marketing rounds up to 'safe.' Chronic-use safety in healthy adults — the actual wellness pattern — has never been characterized, and sustained GH/IGF-1 elevation carries theoretical risks no one has measured for this compound.
Where it stands legally
Never approved; lives in the compounding gray zone with a genuinely fluid FDA status since 2023. Prohibited in tested sport as a GH secretagogue.
Worth asking a licensed provider
- 1.What outcome are we targeting, and what evidence connects ipamorelin to it in humans?
- 2.What is its compounding eligibility today, per the pharmacy you use?
- 3.How will we monitor IGF-1 and glucose, and what's the stop rule?